154 related articles for article (PubMed ID: 37316446)
21. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
22. Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.
Diker O; Olgun P; Balyemez U; Sigit Ikiz S
Cureus; 2023 Jan; 15(1):e33234. PubMed ID: 36733552
[TBL] [Abstract][Full Text] [Related]
23. Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
Epaillard N; Benitez JC; Gorria T; Fabre E; Riudavets M; Reyes R; Planchard D; Oudard S; Viñolas N; Reguart N; Besse B; Mezquita L; Auclin E
Lung Cancer; 2021 May; 155():114-119. PubMed ID: 33798900
[TBL] [Abstract][Full Text] [Related]
24. [Effect of FBXW7 gene mutation on the prognosis of immunotherapy in patients with non-small cell lung cancer].
Liu XY; Cui YN; Li J; Zhang Z; Guo RH
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):914-921. PubMed ID: 35385962
[No Abstract] [Full Text] [Related]
25. Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion.
Li T; Tian P; Huang Q; Zeng H; Wei Q; Li Y
Clin Respir J; 2023 Nov; 17(11):1158-1168. PubMed ID: 37723659
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
Bersanelli M; Buti S; Giannarelli D; Leonetti A; Cortellini A; Russo GL; Signorelli D; Toschi L; Milella M; Pilotto S; Bria E; Proto C; Marinello A; Randon G; Rossi S; Vita E; Sartori G; D'Argento E; Qako E; Giaiacopi E; Ghilardi L; Bettini AC; Rapacchi E; Mazzoni F; Lavacchi D; Scotti V; Ciccone LP; De Tursi M; Di Marino P; Santini D; Russano M; Bordi P; Di Maio M; Audisio M; Filetti M; Giusti R; Berardi R; Fiordoliva I; Cerea G; Pizzutilo EG; Bearz A; De Carlo E; Cecere F; Renna D; Camisa R; Caruso G; Ficorella C; Banna GL; Cortinovis D; Brighenti M; Garassino MC; Tiseo M
Lung Cancer; 2020 Dec; 150():123-131. PubMed ID: 33130353
[TBL] [Abstract][Full Text] [Related]
27. The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis.
Sonehara K; Tateishi K; Araki T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Oncology; 2021; 99(5):271-279. PubMed ID: 33631764
[TBL] [Abstract][Full Text] [Related]
28. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
29. Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review.
Nie NF; Liu ZL; Feng MX; Liu L; Luo N; Li L; He Y
Ann Palliat Med; 2021 Jan; 10(1):210-219. PubMed ID: 33545758
[TBL] [Abstract][Full Text] [Related]
30. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
[TBL] [Abstract][Full Text] [Related]
32. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
Zheng X; Wang H; Zhang G; Yan X; Ma Z
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):513-518. PubMed ID: 30037370
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
Adachi Y; Tamiya A; Taniguchi Y; Enomoto T; Azuma K; Kouno S; Inagaki Y; Saijo N; Okishio K; Atagi S
Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
[TBL] [Abstract][Full Text] [Related]
36. [Exploration of the treatment model for patients with advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease based on real-world data].
Wang F; Xie XH; Lin XQ; Qin YY; Xie ZH; Zhang JX; Ouyang M; Zhou CZ
Zhonghua Jie He He Hu Xi Za Zhi; 2020 May; 43(5):450-454. PubMed ID: 32450634
[No Abstract] [Full Text] [Related]
37. Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients.
Wu Y; Wu H; Lin M; Liu T; Li J
Transl Oncol; 2022 Jan; 15(1):101268. PubMed ID: 34800914
[TBL] [Abstract][Full Text] [Related]
38. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
40. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
